



> **The Company**

ImaRx Therapeutics, Inc. is the world leader in NanoInvasive medicine. As a pioneer in the medical applications of nanotechnology, ImaRx makes it possible for minimally invasive nanoscale drugs to be intelligently deployed yet remotely controlled to fight cardiovascular disease, cancer, and central nervous system disorders.

The first company to start clinical trials in NanoInvasive medicine, ImaRx's mission is to revolutionize medicine through nanotechnology and to provide localized, site-specific, minimally invasive medicine. This form of medicine will provide benefit to patients and society by lowering costs, minimizing pain, and reducing the length of hospital stays and recovery time, while providing improved patient outcomes. The company is in clinical trials for its proprietary SonoLysis technology to treat dialysis grafts and related blood clots and deep vein thrombosis

> **Products**

SonoLysis, ImaRx's lead NanoSurgery program, employs tiny microbubbles and nanobubbles, which are much smaller than a red blood cell, injected into the blood stream to enter into regions of thrombosis. When external ultrasound is applied, the microbubbles cavitate and dissolve blood clots into micron-sized and smaller particles. SonoLysis is designed to painlessly and safely restore blood flow to treat stroke, heart attack, and other conditions. It therefore is a rapid, cost-effective, and safe, method of treating thrombosis.

Compared to other methods of treating vascular thrombosis, SonoLysis has the following potential advantages:

- Rapid restoration of blood flow,
- Less invasive procedure than current thrombectomy devices,
- Site-specific action rather than systemic action (thrombolytics),
- Fewer complications (such as hemorrhage or embolism) compared to thrombectomy devices or thrombolytics.

ImaRx has developed broad nanotechnology platforms to improve patient care through targeted, site-selective therapy. These platforms are protected by over 100 patents and supported by NIH grants. Applications include gene and drug delivery to treat and diagnose vulnerable plaque, cardiovascular disease, cancer, bloodclots, and central nervous system disorders.

> **Management Team**

Dr. Evan Unger, Founder, President & CEO, is an expert on diagnostic imaging, contrast media development, and drug delivery. He has over 80 publications in peer-reviewed journals and more than 140 abstracts presented at major scientific meetings. Dr. Unger is the principal inventor on the majority of the Company's U.S. and foreign patents.

John A. Moore, Chairman of the Board, has been CEO and President of Edson Moore Healthcare Ventures. Since 1994, Mr. Moore has served as CEO and President of Optimer, Inc., a research-based polymer development company. He holds a B.A. in History from Rutgers University.

Terry Matsunaga, PharmD, Ph.D., Vice President, Research, leads an excellent research staff. He received the Excellence in Biotechnology Award for Outstanding Achievement in Drug Delivery.

> **Opportunity**

The company sees unmet medical needs in three crucial areas: deep vein thrombosis, acute limb ischemia, and stroke. And in some of these areas there is little appreciable market competition.

Deep vein thrombosis in the U.S. affects 1.3 to 2.2 million patients each year. The price per dose of nanobubbles is \$2000 and ImaRx net sales are projected to be between \$1–1.4 billion. The projected market share seven years post-entry is expected to be 5% CAGR (compound average growth rate) with an expected peak market penetration between 22% to 30%.

Providing rapid treatment critical to patient outcome, ImaRx has the potential to become the gold standard for treatment of Acute Limb Ischemia. ImaRx has applied for orphan drug status and expects fast track approval. The price per dosage is \$2000, the projected market share after seven years is 5% CAGR with a 70%–76% peak market penetration.

The US incidence of stroke is 616 ischemic stroke patients per year. SonoLysis may extend the current treatment window to nine hours. Cost per dose is \$2000. ImaRx net sales projections are between \$378–528 million with a target market share of 5% CAGR seven years post entry and a peak market penetration at 20% to 28%.

The financial markets are risky. Investing is risky. Past performance does not guarantee future performance. The foregoing has been prepared solely for informational purposes and is not a solicitation, or an offer to buy or sell any security. Offering made by Offering Memorandum only. Opinions are based on historical research and data believed reliable, but there is no guarantee that future results will be profitable. This does not purport to be a complete analysis of the Portfolio Company. The author has relied on information provided by sources deemed to be reputable and although believed to be true, cannot guarantee the accuracy of such information. All claims made by this brochure should be verified by the reader. This brochure is not intended to directly or indirectly provide advice as to the value of any offer described herein, or as to the advisability of investing in such offer. Investing is not suitable for everyone; you should know and understand the risk before making a decision.